The K7 Is Changing the Economics of Security
$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.
These are the 37 donors helping pay for Trump's $300 million White House ballroom
WASHINGTON (AP) — President Donald Trump says his $300 million White House ballroom will be paid for “100% by me and some friends of mine.”
What to know as the annual sign-up window for health insurance arrives
Higher prices, less help and all hang over health insurance markets as shoppers start looking for coverage this week.
America's Next Security Revolution Has Begun - Ad
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
Tempus AI Stock (TEM) Slides 6% Overnight: Here's Why The Stock Is Trending
Tempus AI shares fell 6.02% in after-hours trading Tuesday following its third-quarter earnings report.
Social Security recipients get a 2.8% cost-of-living boost in 2026, average of $56 per month
WASHINGTON (AP) — The cost-of-living increase will go up by 2.8% in 2026, which translates to an average increase of more than $56 for retirees every month, agency officials said Friday.
You're Almost Out of Time to Place This "Debasement Trade" - Ad
Wall Street has been making headlines for piling into a strange new money move they're calling the "Debasement Trade"... And it could affect you and your money in a MAJOR way. According to Dr. David Eifrig the clock is ticking for you to get your money in the right place.
Trump may become the face of economic discontent, a year after such worries helped him win big
WASHINGTON (AP) — President got a serious that he’s out of touch with their fears about a deteriorating U.S. economy.
First clinical trial of pig kidney transplants gets underway
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting might really save lives.
Why Wall Street Is Piling Into the "Debasement Trade" - Ad
Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.
Workers take on side jobs to combat stagnant salaries and insecurity about employment
NEW YORK (AP) — As workers face , inflation and , some have decided to branch out from their traditional careers. They're taking on side jobs to bring in additional income and provide a backup plan should they , or adding second, third and sometimes fourth jobs — what some call “polyworking” — to the mix.
After 50 Years of Chemo, One Biotech Could Lead the Next Cancer Breakthrough - Ad
For decades, toxic chemotherapy defined cancer care. This biotech's innovative approach could finally change that. With early results showing precision without poison, this story is one investors will want to see early.
2 new malaria treatments announced as drug resistance grows
NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs.
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit before November 18's bombshell.
House returns for vote to end the government shutdown after nearly 2 months away
WASHINGTON (AP) — House lawmakers will make a long-awaited return to the nation's capital on Wednesday after nearly eight weeks away to potentially put an end to the longest in U.S. history.
FDA names longtime cancer scientist Pazdur to lead drug center
WASHINGTON (AP) — The Food and Drug Administration on Tuesday named a longtime regulator of cancer medicines to lead the agency's drug center, replacing the who was recently ousted after an .
The K7 Is Changing the Economics of Security - Ad
$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as January 29.
Landmark Paris Agreement set a path to slow warming. The world hasn't stayed on it
The world has changed dramatically in the decade since leaders celebrated a a decade ago, but not quite in ways they expected or wanted.
What to know about COP30, this year's UN climate talks
People from around the world are beginning to gather at the gateway of the Amazon in Belem, Brazil, for the 30th annual United Nations climate summit, the Conference of the Parties, known less formally as COP30.
Speculative? Yes. But This Memecoin Has Serious Fundamentals. - Ad
Most memecoins are driven by hype-but this one might be different. Backed by a real use case and unexpected investor interest, our analysts believe it could emerge as one of the strongest performers in the coming cycle.
Embed-Chart-Protecting Miners, ADVISORY
PROTECTING MINERS — Chart. This AP digital embed chart shows the percentage of longterm coal miners since 1974 tested for black lung disease who were found to have the ailment. After two decades of declines, the numbers have risen again, most prominently among miners in the central Appalachian region that includes Kentucky, Virginia and West Virginia. This chart is current as of Nov. 3, 2025, and will not update. Source: NIOSH Coal Workers’ Health Surveillance Program.
Last monkey on the loose after Mississippi highway crash is captured after being spotted by resident
HEIDELBERG, Miss. (AP) — The last monkey on the loose among several that escaped after a Mississippi highway crash has been found and captured, authorities said Thursday.
Another Gold High? Here's the Move Wall Street Is Missing ... - Ad
Gold just surged past $4,200, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.
Some Social Security Recipients Won't Have To Wait Until 2026 For COLA Hike
Social Security and SSI recipients will receive a 2.8% cost-of-living adjustment in 2026, with SSI beneficiaries seeing the increase a day earlier due to a federal holiday.
Charles River Beat Expectations But Why Is The Stock Falling?
Charles River stock dips as Q3 revenue slips, EPS beats estimates, and company raises 2025 outlook with cost cuts and $1 billion buyback plan.
AI Meets Real-World Security with the K7 - Ad
Continuous patrols. Instant response. Zero fatigue. The K7 merges robotics and data to outperform humans in coverage, cost, and consistency and it's already live across the US.
Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.
America's Next Security Revolution Has Begun - Ad
Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.
Uncertainty over federal food aid deepens as the shutdown fight reaches a crisis point
WASHINGTON (AP) — The crises at the heart of the in Washington were coming to a head Saturday as the faced delays and millions of Americans were set to see a dramatic rise in their .
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk
Pfizer is suing over in its nearly $5 billion bid to buy the drugmaker Metsera.
You're Almost Out of Time to Place This "Debasement Trade" - Ad
Wall Street has been making headlines for piling into a strange new money move they're calling the "Debasement Trade"... And it could affect you and your money in a MAJOR way. According to Dr. David Eifrig the clock is ticking for you to get your money in the right place.
Federal health officials push effort to spur cheaper biotech drugs
Federal regulators are trying to make it easier to develop to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers.
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.